Cancer Medicine, Год журнала: 2025, Номер 14(7)

Опубликована: Март 27, 2025

ABSTRACT Introduction Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the current standard of care for first‐line (1L) treatment hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (mBC). To investigate effectiveness palbociclib, first‐in‐class CDK4/6i, plus an aromatase inhibitor (AI) older patients, we compared overall survival (OS) a Medicare population treated 1L palbociclib + AI versus alone. Methods Patients aged ≥ 65 years who were diagnosed de novo HR+/HER2– mBC from 2015 to 2019 identified Surveillance, Epidemiology, End Results (SEER)–linked database eligible if they initiated or The primary endpoint was OS. Stabilized inverse probability weighting (sIPTW) used balance baseline patient characteristics. Of 779 296 received 483 alone as treatment. After sIPTW, median follow‐up 23.1 months 18.2 Adjusted OS longer (sIPTW: 37.6 vs. 25.5 months, HR = 0.73 [95% CI, 0.59–0.91]). In multivariable Cox proportional hazards regression, patients had 39% lower risk death (HR 0.61 0.48–0.77]). Conclusion routine US clinical practice, associated significantly prolonged mBC, adding growing body evidence on benefit this population. Trial Registration ClinicalTrials.gov identifier: NCT06086340

Язык: Английский